One molecule to block both pain and itch
A new antibody appears to block 2 unpleasant nerve signals. Duke University researchers have found an antibody that simultaneously blocks the sensations of pain and itching in studies… read more.
A new antibody appears to block 2 unpleasant nerve signals. Duke University researchers have found an antibody that simultaneously blocks the sensations of pain and itching in studies… read more.
Researchers at King’s College London have discovered a link between four common chronic pain syndromes (CPS), suggesting that some people may be genetically predisposed to suffer from conditions… read more.
Researchers may have identified key genes linked to why some people have a higher tolerance for pain than others, according to a study released today that will be… read more.
Non-invasive focused ultrasound thermal therapy reduces pain from bone metastases. When cancer progresses and spreads to the bone, patients often suffer debilitating pain. Now, a new phase III… read more.
by Bruce Sylvester – The presence of the single nucleotide polymorphism (SNP) rs895374, located in UbcH7, an E2 ligase conducting neddylation of HECT E3 ligases involved in EGFR… read more.
by Bruce Sylvester – Intermittent strategies for delivering systemic treatment in metastatic colorectal cancer show no clinically significant superiority in overall survival rates when compared to continuous delivery,… read more.
This year saw the first of an exciting new style of conference. The Urology QT Conference was based on a ‘Question Time’ format that encouraged lively debate and… read more.
by Bruce Sylvester – In the FIRE 3 trial, clinicians favored the use of second-line antibodies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) with shorter first-line progression free… read more.
by Bruce Sylvester – KRAS exon 2 mutations are independent predictors of time to recurrence or disease-free survival among patients with stage III distal colon cancer who are receiving… read more.
by Bruce Sylvester – Metastatic colorectal cancer patients who achieved early response to first-line chemotherapy also achieved significantly higher rates of prolonged survival, compared to patients who did… read more.
by Bruce Sylvester – Survival based on primary site of disease is not significantly different among metastatic colorectal cancer patients, Australian researchers reported in a poster presentation at… read more.
Adapted from Abstract 3506, which was submitted to ASCO Congress 2014 Treatment outcome according to tumour RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.